Who is sponsoring NCT05922917?

NCT05922917 is sponsored by České Budějovice Hospital.

What drugs are being tested in NCT05922917?

Interventions in NCT05922917: pulsed-field ablation.

What condition does NCT05922917 study?

NCT05922917 studies Persistent Atrial Fibrillation, Pulsed-field Ablation.

Is NCT05922917 still recruiting?

NCT05922917 is currently active, enrolled. Last updated 18 March 2026.

Last reviewed 2026-03-18 · How we verify

NCT05922917: PIVCO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulsed-field Ablation in Patients With Persistent Atrial Fibrillation

Active, enrolled NA Last updated 18 March 2026

What this trial tests

NA trial testing pulsed-field ablation in Persistent Atrial Fibrillation in 300 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 June 2023

Primary endpoint
30 June 2026

30 November 2026

Quick facts

Lead sponsor	České Budějovice Hospital
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	300
Start date	20 June 2023
Primary completion	30 June 2026
Estimated completion	30 November 2026
Sites	3 locations across Czechia

Drugs / interventions tested

pulsed-field ablation

Conditions studied

Persistent Atrial Fibrillation — all drugs for Persistent Atrial Fibrillation →
Pulsed-field Ablation — all drugs for Pulsed-field Ablation →

Sponsor

České Budějovice Hospital

Who can join

Adults 18 to 75, any sex, with Persistent Atrial Fibrillation or Pulsed-field Ablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since a new method called pulsed-field ablation (PFA) has emerged, allowing significantly simpler, safer, and faster creation of ablative lesions in paroxysmal AF and PsAF (13), redefining the "optimal" ablation approach started to appear mandatory. Our project (The PIVCO study) aims to determine a more standardized procedure representing optimal ablation strategy for patients suffering from PsAF using PFA and multielectrode ablation catheters. The central hypothesis is that ablation of the posterior LA wall (PWI), together with mitral and cavotricuspid isthmus ablation added on top of PVI, will be associated with better effects in terms of rhythm control. Given the speed, safety, and ease of standardization of ablation using electroporation, a demonstration of the superiority of either approach could significantly impact the current standard of clinical care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Atrial Fibrillation Ablation During Hospitalization for Acute Heart Failure: Feasibility and Role of Pulsed Field Ablation.
Marek J, Stojadinović P, Wichterle D, Peichl P, et al · · 2025 · cited 1× · PMID 39588593 · DOI 10.1111/jce.16507

Verify or expand the search:

Other recruiting trials for Persistent Atrial Fibrillation

Currently open trials in the same condition.

NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp · NA · recruiting
NCT07535268 — REPRESENT-PF Registry · recruiting
NCT07508618 — Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule · Phase 4 · recruiting
NCT07116525 — A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter · NA · recruiting
NCT07106970 — PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05922917 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by České Budějovice Hospital
Last refreshed: 18 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05922917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing